Blood Cancer NZ commissioned Deloitte to develop the State of Blood Cancer report to provide, for the first time, a comprehensive and evidence-based picture of blood cancer in New Zealand. Blood cancers are often misunderstood and underrepresented in national reporting, despite being one of the country’s most significant and fastest growing cancer burdens. By bringing together national data, clinical insight, and the lived experiences of patients and whānau, this report seeks to make visible the true scale and complexity of blood cancer, and the unique way it depends on timely diagnosis, specialist care, and access to effective treatments.

The report was also developed to identify where New Zealand is falling behind what is achievable internationally, and to set a clear direction for change. It highlights critical gaps in treatment access, system capacity, and coordination that are directly impacting outcomes for patients. By consolidating this evidence into a single, authoritative source, Blood Cancer NZ aims to inform policy, support clinical and system planning, and drive a coordinated response across government and the health system, with the goal of ensuring that no lives are needlessly lost to blood cancer.